ENERGIF-703 is under clinical development by Energenesis Biomedical and currently in Phase III for Diabetic Foot Ulcers. According to GlobalData, Phase III drugs for Diabetic Foot Ulcers does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ENERGIF-703 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ENERGIF-703 overview
ENERGIF-703 is under development for the treatment of diabetic foot ulcers, venous leg ulcer and hereditary epidermolysis bullosa. The drug candidate is formulated as a gel and is administered through topical route. It acts by targeting AMPK (AMP activated protein kinase). The drug candidate is developed based on Energi technological platform.
Energenesis Biomedical overview
Energenesis Biomedical (Energenesis) is a biomedicine company that focuses on the development of new medicines using its proprietary ENERGI platform. The platform utilizes the activation of AMP activated protein kinase (AMPK) to enhance cellular energy. Its product pipeline includes medicines such as ENERGI-F703 and ENERGI-F701. Energenesis’ products are primarily used by scientific researchers in the biomedical industry. The company collaborates with domestic and international academic and research bodies for the development of its products. Energenesis is headquartered in Taipei, Taiwan.
For a complete picture of ENERGIF-703’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
